Could a common diabetes drug boost chemotherapy against pancreatic cancer?
NCT ID NCT05947825
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This phase 2 trial investigates whether adding sitagliptin, a diabetes medication, to standard chemotherapy (gemcitabine and nab-paclitaxel) can improve outcomes for people with advanced pancreatic cancer that has not been treated before. The study enrolls 30 adults with locally advanced or metastatic pancreatic ductal adenocarcinoma. The main goal is to see if the combination extends the time patients live without their cancer progressing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sitagliptin combined with gemcitabine and nab-paclitaxel
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with advanced pancreatic cancer, potentially extending the time before the disease worsens.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply to all patients. Adding sitagliptin could also increase side effects from chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PDAC - PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New laser blood test could spot pancreatic cancer early
- New hope for hard-to-treat pancreatic cancer: targeted drug combo enters phase 3 trial
- Blood test hunt for silent killer: 5,000 High-Risk volunteers sought
- Supercharged t cells take on Hard-to-Treat cancers
- Massive cancer registry aims to unlock better GI cancer care
- Last-Resort drug access opens for advanced pancreatic cancer patients